Tasigna Description

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Full Prescribing Info

Description

150 mg Hard Capsules: Each capsule contains 150 mg nilotinib base (as hydrochloride, monohydrate).
200 mg Hard Capsules: Each capsule contains 200 mg nilotinib base (as hydrochloride, monohydrate).
Excipients/Inactive Ingredients: 150 mg Hard Capsules: Capsule Content: Lactose monohydrate, crospovidone, poloxamer 188, silica colloidal, anhydrous/colloidal silicon dioxide, magnesium stearate.
Capsule Shell: Gelatin, titanium dioxide (E 171), iron oxide red (E 172), iron oxide yellow (E 172).
Printing Ink: Iron oxide black (E 172).
200 mg Hard Capsules: Capsule Content: Lactose monohydrate, crospovidone, poloxamer 188, silica colloidal, anhydrous/colloidal silicon dioxide, magnesium stearate.
Capsule Shell: Gelatin, titanium dioxide (E 171), iron oxide yellow (E 172).
Printing Ink: Iron oxide red (E 172), iron oxide black (E 172).

nilotinib

Manufacturer:

Novartis Healthcare

Distributor:

Novartis Healthcare